LFG
ACAD icon

Larson Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Larson Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5K Buy
891
+12
+1% +$264 ﹤0.01% 1944
2026
Q1 		$19.6K Buy
879
+768
+692% +$18.4K ﹤0.01% 1864
2025
Q4 		$2.96K Buy
111
+66
+147% +$1.58K ﹤0.01% 2672
2025
Q3 		$960 Buy
45
+34
+309% +$804 ﹤0.01% 2935
2025
Q2 		$237 Buy
+11
New +$204 ﹤0.01% 3030

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Larson Financial Group's ACAD Position: Q2 2026 in Review

Larson Financial Group increased its Acadia Pharmaceuticals (ACAD) stake by 1.4% in Q2 2026, buying an estimated $264 and bringing the position to 891 shares worth $22.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1944.

Larson Financial Group first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Larson Financial Group held 891 shares of Acadia Pharmaceuticals worth $22.5K as of Q2 2026.
  • Larson Financial Group bought 12 Acadia Pharmaceuticals shares in Q2 2026, an estimated $264.
  • Acadia Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1944 holding.
  • Larson Financial Group first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.